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Abstract
Human trophoblast expresses two fusogenic retroviral envelope proteins, the widely studied
syncytin 1, encoded by HERV-W and the recently characterized syncytin 2 encoded by HERV-FRD.
Here we studied syncytin 2 in normal and Trisomy 21-affected placenta associated with abnormal
trophoblast differentiation. Syncytin 2 immunolocalization was restricted throughout normal
pregnancy to some villous cytotrophoblastic cells (CT). During the second trimester of pregnancy,
syncytin 2 was immunolocalized in some cuboidal CT in T21 placentas, whereas in normal placentas
it was observed in flat CT, extending into their cytoplasmic processes. In vitro, CT isolated from
normal placenta fuse and differentiate into syncytiotrophoblast. At the same time, syncytin 2
transcript levels decreased significantly with syncytiotrophoblast formation. In contrast, CT
isolated from T21-affected placentas fused and differentiated poorly and no variation in syncytin 2
transcript levels was observed. Syncytin 2 expression illustrates the abnormal trophoblast
differentiation observed in placenta of fetal T21-affected pregnancies.
Background
Human endogenous retroviruses (HERV) comprise
approximately 8% of the human genome [1,2]. Most of
the identified elements are defective due to mutations
and/or deletions within their genes, but some elements
have conserved intact open reading frames. A systematic
search for non-defective endogenous retrovirus envelope
protein genes has led to the identification of 16 genes [3].
Among them, two can induce cell-cell fusion when
expressed in different cells and are highly and specifically
expressed in the human placenta [4-6]. The products of
these two genes are glycoproteins named HERV-W Env
glycoprotein (syncytin 1) and HERV-FRD Env glycopro-
tein (syncytin 2).
In the human placenta, the trophoblast differentiates
along two major pathways both critical for normal pla-
cental function [7]. In the extravillous trophoblast inva-
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sive pathway, the cytotrophoblastic cells of the anchoring
villi in contact with the uterus wall proliferate, detach
from the basement membrane and aggregate into multi-
layered columns of non-polarized cells that invade the
uterus wall (Fig. 1). These cells, which compose the
extravillous cytotrophoblast (ECT), invade the
endometrium, the first third of the myometrium and the
associated spiral arterioles. In the villous trophoblast
pathway, the cytotrophoblastic cells of the floating villi
proliferate, differentiate and fuse to form a syncytiotro-
phoblast (ST) that covers the entire surface of the villi (Fig.
1). The syncytiotrophoblast layer plays a major role
throughout pregnancy, since it is the site of numerous pla-
cental functions, including ion and nutrient exchange and
the synthesis of steroid and peptide hormones required
for fetal growth and development. This multinucleated
syncytiotrophoblast is regenerated along pregnancy by a
continuous turnover process including proliferation of
underlaying mononuclear cytotrophoblasts (CT), fusion
of these cytotrophoblasts into syncytiotrophoblast and
progression toward apoptosis.
In vitro isolated mononuclear cytotrophoblasts aggregate
and fuse together to form a non proliferative, multinucle-
ated syncytiotrophoblast which secretes human chorionic
gonadotropin (hCG) and human placental lactogen
(hPL), specific to pregnancy [8,9].
Trisomy of chromosome 21 (T21), which causes the phe-
notype known as Down syndrome, is the major known
genetic cause of mental retardation and is found in
around 1:800 live births. Little is known about placental
development in this aneuploid condition. However, a
defect in syncytiotrophoblast formation in T21-affected
placentas is observed. Cultured cytotrophoblasts, isolated
from T21-affected placentas, aggregate but fuse poorly or
belatedly [10-13].
Trophoblast fusion and differentiation directly involves
different molecular actors [14]. Among them, the HERV-
W envelope glycoprotein named syncytin 1 is expressed in
all trophoblastic cells [15,16] and directly involved in
human trophoblast fusion and differentiation [17].
HERV-FRD Env glycoprotein (or syncytin 2) has been
more recently shown to be expressed in the human pla-
centa [1,4,18]. The aim of this work was therefore to study
in situ and in vitro the expression and localization of syn-
cytin 2 in human placenta at different stages of gestation,
in normal and T21-affected pregnancies.
Results
Syncytin 2 is immunolocalized in cytotrophoblastic cells 
throughout normal pregnancy
Figure 2 shows the syncytin 2 immunolocalization in cho-
rionic villi throughout normal pregnancy. In first trimes-
ter placenta (Fig. 2A–B), syncytin 2 was only detected at
the level of the cytotrophoblastic cells, which form a con-
tinuous single layer of cuboidal cells beneath the syncyti-
otrophoblast. Immunostaining was observed only in the
cytoplasm of some cytotrophoblastic cells and never
observed in the syncytiotrophoblast and in the mesenchy-
mal core of the villi (Fig. 2A–B). In second trimester pla-
centa (Fig. 2C–D), syncytin 2 immunostaining was
present: 1/in the cytoplasm of cytotrophoblastic cells; 2/
in their thin elongated cytoplasmic processes coming into
contact with the syncytiotrophoblast and covering the vil-
lus basal lamina. At term (Fig. 2E–F), immunostaining
was detected at low magnification in a fraction of the flat
cytotrophoblastic cells and extended into their thin cyto-
plasmic processes. Higher magnification showed the con-
tinuity of syncytin 2 immunostaining between the
cytoplasm surrounding the nuclei and that of the thin
elongated cytoplasmic processes.
Syncytin 2 immunostaining of cytotrophoblastic cells 
differs between T21 and gestational age-matched control 
placentas
A striking difference was observed between T21 second tri-
mester placentas (18–19 weeks of gestation) and age-
matched controls (Fig. 3). Indeed, as previously
described, an increase in the thickness of the trophoblastic
layer was observed in T21-placenta. As shown in figure 4,
syncytin 2 was immunolocalized in some cuboidal
cytotrophoblastic cells beneath the syncytiotrophoblast in
T21 placentas (Fig. 4C–D). In gestational age-matched
controls, syncytin 2 was observed in some flat cytotro-
phoblastic cells and extended into their thin elongated
cytoplasmic processes (Fig. 4A–B), as already noted
above.
With time in culture Syncytin 2 transcript levels decrease 
in normal but not in T21 cells
Cytotrophoblastic cells isolated from the chorionic villi of
second trimester normal placentas adhere to plastic
dishes, aggregate and fuse together to form a syncytiotro-
phoblast within 48 to 72 hours (Fig. 5 upper panel). Syn-
cytin 2 positive immunostaining was only observed in
some cytotrophoblastic cells forming aggregates; the
staining was more intense at the sites of contact between
these syncytin 2-positive, aggregated cells (data not
shown). No immunostaining was observed in multinucle-
ated syncytiotrophoblast after 48 or 72 hours of culture.
Cytotrophoblastic cells isolated from T21-affected placen-
tas adhered to the plastic dishes, aggregated, but did not
fuse or fused only after a delay and poorly differentiated
into syncytiotrophoblast (Fig. 5 T21). This was not associ-
ated with any significant increase in hCG secretion during
the 72 hours of culture (Fig. 5 bottom panel). In these T21
trophoblastic cells, syncytin 2 transcript levels did not
vary during the 72 hours of culture (Fig. 5 bottom panel).Retrovirology 2008, 5:6 http://www.retrovirology.com/content/5/1/6
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A. In humans, at 10–12 weeks of pregnancy, the chorionic floating villi are in contact with the maternal blood in the maternal  blood space (MBS) Figure 1
A. In humans, at 10–12 weeks of pregnancy, the chorionic floating villi are in contact with the maternal blood in the maternal 
blood space (MBS). In these villi, cytotrophoblastic cells (CT) differentiate by fusion to generate the syncytiotrophoblast (ST). 
In the anchoring villi the cytotrophoblastic cells proliferate and invade the decidua (DC). The extravillous cytotrophoblastic 
cells (ECT) invade the lumen of uterine arteries (UA). FC: Fetal capillary; M: mesenchyme. B. Evolution of human floating cho-
rionic villi. The chorionic villi, in direct contact with the maternal blood in the maternal blood space (MBS), consist of cytotro-
phoblastic cells (CT) and syncytiotrophoblast (ST) surrounding a core of mesenchymal cells including fetal capillaries (FC), 
fibroblasts (F) and Hofbauer cells (HC). BL: basal lamina.
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Immunohistochemical analysis of syncytin 2 (HERV-FRD Env) in human placenta Figure 2
Immunohistochemical analysis of syncytin 2 (HERV-FRD Env) in human placenta. Top panel. First trimester float-
ing villi (8 weeks of pregnancy). A. Syncytin 2 was detected in some cytotrophoblastic cells (CT). No immunostaining was 
observed in the syncytiotrophoblast (ST) and in the mesenchymal core (MC). Scale bar = 10 µm. B. This large magnification 
allows to clearly establish the cytoplasmic localization of syncytin 2 immunostaining in a pair of cytotrophoblastic cells. At this 
gestational age the cytotrophoblast consists of a continuous single layer of cuboidal cells beneath the syncytiotrophoblast. Scale 
bar = 10 µm. Arrowhead: non labeled CT, arrow: positively stained CT. Middle panel. Second trimester placenta (16 weeks of 
pregnancy). C. Immunostaining with anti-syncytin2 antibody shows positive reactivity in some cytotrophoblastic cells. No syn-
cytin 2 reactivity was detected in the extravillous trophoblast (ECT), in the syncytiotrophoblast and in the mesenchymal core. 
Scale bar = 10 µm. D. In this floating villi, syncytin 2 immunostaining was observed in the cytoplasm of some cytotrophoblastic 
cells (arrow), in their thin cytoplasmic processes (star) and at the level of the trophoblastic basal lamina (double head arrow). 
Scale bar = 10 µm. Bottom panel. Term placenta floating villi. E. Syncytin 2 was detected in the cytoplasm surrounding the 
nuclei of flat cytotrophoblastic cells and in their thin elongated cytoplasmic processes. Staining was absent from some villi. Scale 
bar = 10 µm. F. This large magnification allows to clearly establish the syncytin 2 immunostaining continuity within cytotro-
phoblasts between the cytoplasm surrounding the nuclei and that of the thin cytoplasmic processes. Scale bar = 10 µm.Retrovirology 2008, 5:6 http://www.retrovirology.com/content/5/1/6
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In contrast, in trophoblastic cells isolated from age-
matched control placentas, the in vitro formation of syncy-
tiotrophoblast was associated with a drastic increase in
hCG secretion and syncytin 2 transcript levels decreased
significantly (p < 0.02) between 24 and 72 hours of cul-
ture (Fig. 5).
Discussion
The role of endogenous retroviruses in placental morpho-
genesis and trophoblast differentiation was hypothesized
10 years ago [19]. More recent studies point to the pres-
ence of HERV-R (ERV 3), HERV-FRD, HERV-W, HERV-F,
HERV-K and HERV-T in human placenta, coding for intact
retroviral Env proteins [3]. However the role of theses ret-
roviral envelope proteins is still poorly understood.
A role for the ERV-3 envelope protein (produced by the
single-copy human endogenous retrovirus ERV-3) have
been suggested in trophoblast proliferation and differen-
tiation [20,21]. However, the physiological knockout of
the ERV-3 envelope (lacking both the fusion peptide and
the immunosuppressive domain) in 1% of the Caucasian
population [22] suggests that no essential function in pla-
centation is associated with the expression of the ERV-3
envelope protein.
HERV-W envelope protein, syncytin 1, is directly involved
in villous trophoblast fusion and differentiation [17]. The
syncytin 1 is expressed in all trophoblastic cells, villous
and extravillous trophoblast, independently of their dif-
ferentiation stage [15,16].
In this study, we show that throughout pregnancy, HERV-
FRD envelope protein, syncytin 2 is detected in some vil-
lous cytotrophoblastic cell and therefore this localization
differs from syncytin 1 localization. All along pregnancy,
the syncytiotrophoblast regenerates from the fusion of the
underlying cytotrophoblasts. This process includes the
continuous trophoblast turnover including proliferation
of cytotrophoblast progenitors, the withdrawal of cytotro-
phoblasts from the cell cycle to G0, the recruitment of
these post-mitotic cells to syncytiotrophoblast after mem-
brane fusion and progression of syncytiotrophoblast
towards apoptosis. Therefore the expression of syncytin 2
in some cytotrophoblastic cells suggest that it is expressed
when the cytotrophoblastic cell is engaged in the fusion
stage. As illustrated in second trimester placenta cytotro-
phoblastic cells are immunostained for syncytin 2 more
frequently at the level of the cell membrane and this stain-
ing occurs at the sites of contact with the syncytiotrophob-
last. Localization at this interface is precisely that expected
for a protein directly involved in the fusion of the mono-
nuclear cytotrophoblastic cells into the syncytiotrophob-
last.
In addition, the syncytin 2 immunolabeling reflects the
structural changes of the cytotrophoblastic layer during
pregnancy. Indeed, as recently demonstrated, the cytotro-
Second trimester chorionic villi of normal (19 weeks of amenorrhea: wa) and trisomy 21 (18 wa) placentae Figure 3
Second trimester chorionic villi of normal (19 weeks of amenorrhea: wa) and trisomy 21 (18 wa) placentae. In normal placenta, 
a large amount of cytotrophoblastic cells (CT) have fused into a thin multinucleated syncytiotrophoblast (ST). In trisomy 21 
placenta, many cuboidal cytotrophoblastic cells (CT) are still present beneath the syncytiotrophoblast (ST) increasing the thick-
ness of the trophoblastic layer. Scale bar = 10 µm.
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Immunohistochemical analysis of syncytin 2 (HERV-FRD Env) in age-matched second trimester (19 weeks) normal (upper  panel) and T21-affected placentas (lower panel) Figure 4
Immunohistochemical analysis of syncytin 2 (HERV-FRD Env) in age-matched second trimester (19 weeks) normal (upper 
panel) and T21-affected placentas (lower panel). Upper panel A. Immunostaining with anti-syncytin2 antibody showed positive 
reactivity in a fraction of elongated cytotrophoblastic cells. Scale bar = 10 µm. B. In this large magnification, syncytin 2 immu-
nostaining was observed in the cytoplasm of cytotrophoblastic cells and in the thin cytoplasmic processes. Scale bar = 10 µm. 
Lower panel C. Syncytin 2 was detected in some cuboidal cytotrophoblastic cells. Scale bar = 10 µm. D. This high magnifica-
tion shows the cytoplasmic localization of syncytin 2 immunostaining in several cytotrophoblastic cells. Scale bar = 10 µm.Retrovirology 2008, 5:6 http://www.retrovirology.com/content/5/1/6
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Morphological differentiation (upper panel), real-time RT-PCR analysis of syncytin 2 (HERV-FRD env) transcripts (lower left  panel) and hCG secretion (lower rigth panel) during in vitro culture of control and T21 trophoblastic cells Figure 5
Morphological differentiation (upper panel), real-time RT-PCR analysis of syncytin 2 (HERV-FRD env) transcripts (lower left 
panel) and hCG secretion (lower rigth panel) during in vitro culture of control and T21 trophoblastic cells. Cytotrophoblastic 
cells were purified from three distinct age matched (second trimester) control and T21-affected placentas and separately cul-
tured. The cells were visualized under phase contrast light microscopy (Scale bar = 10 µm). At 72 h, normal cytotrophoblastic 
cells had fused resulting in the formation of a large syncytium containing numerous nuclei. In contrast, T21 cytotrophoblasts 
were still aggregated and had not fused. Total mRNA were extracted after 24 and 72 h of culture. Data are expressed as the 
level of syncytin 2 mRNA normalized to that of RPLP0 mRNA. HCG secretion into the culture medium was measured at the 
indicated times, in normal (N) and T21-affected cell cultures. Results are the means ± SEM of triplicate dishes from three differ-
ent cultures.
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phoblastic cell layer becomes thinner: the cuboidal cells
are transformed to flat cells with many cellular processes
that together with those of the adjacent syncytiotrophob-
last eventually cover the basal lamina in a complex net-
work of interdigitations [23].
In T21-affected placentas, localization of the labeled syn-
cytin 2 differs notably from that in gestational age-
matched control placentas. Syncytin 2 is mainly located in
the cytoplasm of cuboidal cytotrophoblastic cells. This
observation highlights in situ the delay in the fusion proc-
ess of T21 trophoblastic cells and the delay in the matura-
tion of the chorionic villi from T21-affected placentas
[24,25] (Fig. 3).
In addition the transcript levels of syncytin 2 decreased
significantly during in vitro differentiation of normal
cytotrophoblastic cells into syncytiotrophoblast. In con-
trast in isolated T21 cytotrophoblastic cells, which did not
fuse transcript levels of syncytin 2 did not vary with time
in culture. Interestingly, we recently demonstrated that
the in vitro defect of syncytiotrophoblast formation in T21
is reversible when cytotrophoblastic cells are treated with
biosynthetic human chorionic gonadotropin. These
results point to a major role of abnormal hCG and its
receptor in T21 placental defect [26].
Envelope glycoprotein of HERV-W (syncytin 1) [17] inter-
acts with its identified receptor RDR, also known as the
neutral aminoacid transporter SLC1A5/ASCT2 [5,27].
Syncytin 2 entered the primate genome earlier than syncy-
tin 1, namely before the split between New World and
Old World Monkeys (i.e >40 Myrs ago). It also differs in
its receptor, as demonstrated by ex vivo cell-cell fusion
assays using different cell types [4]. The identification of
this receptor and the direct role of syncytin 2 of in human
syncytiotrophoblast formation need to be investigated.
Recently, other retroviral envelope proteins have been
identified in placenta from other species. In mouse pla-
centa two related env genes (syncytin A and syncytin B)
were characterized [28] and it was demonstrated that the
endogenous Jaagsiekte sheep retrovirus envelope regu-
lates trophectoderm growth and differentiation in perim-
plantation ovine conceptus [29]. The role of these
retroviral envelope proteins in fetoplacental development
is still poorly known but their pleiotropic functions,
including immunosuppressive activity argue for a critical
role [1,30,31].
Conclusion
In summary data presented here show that the highly
fusogenic retroviral FRD envelop protein, syncytin 2, is
expressed in human placenta throughout pregnancy in
some cytotrophoblastic cells, which might be in the
fusion stage. Syncytin 2 expression highlights the abnor-
mal trophoblast differentiation observed in placenta of
fetal T21-affected pregnancies.
Methods
Placenta collection
First trimester placentas were obtained from legal induced
abortions (8–12 weeks of gestation). Term placentas were
obtained after elective cesarean section from healthy
mothers near term with uncomplicated pregnancies. Sam-
ples of second trimester placental tissues were collected at
the time of termination of pregnancy at 12–25 weeks of
gestation (in weeks of amenorrhea) in T21-affected preg-
nancies (n = 5) and gestational age-matched control cases
(n = 5) as previously described [10]. Fetal Down syn-
drome was diagnosed by karyotyping of amniotic fluid
cells, chorionic villi or fetal blood cells. Termination of
pregnancy was performed in control cases affected by
severe bilateral or low obstructive uropathy or major car-
diac abnormalities. The karyotype of placental cells was
checked in all cases (free trisomy 21 or normal). The use
of these biological samples was approved by our local eth-
ical committee.
Immunohistochemistry
Placental samples were fixed in 4% formalin for 4–12 h at
room temperature and then embedded in paraffin.
Briefly, paraffin sections were dewaxed in xylene and rehy-
drated in ethanol/water. Some sections were classically
stained with H&E. Immunostaining was performed with
an universal streptavidin-peroxidase immunostaining kit
(Dako LSAB, Glostrup, Danemark) using a syncytin 2
monoclonal antibody [18]. All controls, performed with a
mouse isotypic IgG1 at the same concentration as the pri-
mary antibody were negative.
Cell culture
For in vitro culture villous cytotrophoblastic cells were iso-
lated from second trimester placentas (gestational age-
matched controls and T21-affected placentas). 90%–95%
of the cells isolated from the normal or T21 placentas
were cytokeratin 7-positive. Cells plated in triplicate were
cultured for 3 days. Trophoblastic fusion was monitored
by desmoplakin immunostaining and nuclei counting as
previously described [14].
Quantification of specific transcripts by real-time RT-PCR
Total RNA was extracted from villous trophoblastic cells
cultured for 24 h and 72 h using QIAGEN RNeasy mini
kit. cDNA synthesis and PCR amplification were per-
formed as described previously [10]. All PCR reactions
were performed using an ABI Prism 7700 Sequence Detec-
tion System and the SYBER Green PCR Core Reagents kit
(Perkin-Elmer). We used the following primers: FRD (+)
5'-GCCTGC A AATAGTCTTCTTT-3' and FRD (-) 5'-ATAG-Retrovirology 2008, 5:6 http://www.retrovirology.com/content/5/1/6
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GGGCTATTCCCATTAG-3'. RNA from the RPLP0  gene
encoding the human acidic ribosomal phosphoprotein-
P0 was used as an internal control and each sample was
normalized to RPLP0 transcript content. The RPLP0 prim-
ers used for amplification were: (+) 5'-GGCGACCTGGAA
GTCCAAT-3' and (-) 5'-CCATCAGCACCA CAGCCTTC-3'.
Hormonal assay
The hCG concentration was determined in culture
medium at 24 h and 72 h of culture, using an enzyme.
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